X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2134) 2134
Publication (133) 133
Book Review (17) 17
Newsletter (8) 8
Book / eBook (5) 5
Newspaper Article (5) 5
Book Chapter (4) 4
Magazine Article (4) 4
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1295) 1295
male (1189) 1189
animals (949) 949
female (754) 754
hypercholesterolemia (750) 750
hypercholesterolemia - chemically induced (676) 676
index medicus (662) 662
hypercholesterolemia - drug therapy (652) 652
middle aged (504) 504
cholesterol (466) 466
cholesterol - blood (440) 440
rats (404) 404
adult (402) 402
aged (311) 311
atherosclerosis (309) 309
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (295) 295
pharmacology & pharmacy (287) 287
risk factors (273) 273
hypercholesterolemia - blood (257) 257
rabbits (237) 237
hypercholesterolemia - complications (223) 223
mice (215) 215
triglycerides - blood (215) 215
statins (200) 200
lipids - blood (192) 192
hypercholesterolemia - metabolism (182) 182
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (177) 177
disease models, animal (176) 176
anticholesteremic agents - adverse effects (175) 175
lipids (174) 174
cholesterol, ldl - blood (164) 164
cardiac & cardiovascular systems (162) 162
biochemistry & molecular biology (161) 161
medicine, general & internal (159) 159
anticholesteremic agents - therapeutic use (153) 153
peripheral vascular disease (151) 151
simvastatin (150) 150
liver - metabolism (146) 146
hyperlipidemia (142) 142
muscular diseases - chemically induced (138) 138
time factors (135) 135
diet (133) 133
cholesterol - metabolism (131) 131
liver - drug effects (126) 126
lipoproteins (125) 125
risk (125) 125
research (123) 123
rats, wistar (122) 122
therapy (121) 121
treatment outcome (120) 120
metabolism (118) 118
oxidative stress (114) 114
dose-response relationship, drug (113) 113
disease (109) 109
analysis (105) 105
hyperlipidemias - chemically induced (104) 104
low density lipoproteins (102) 102
physiological aspects (102) 102
cholesterol, hdl - blood (101) 101
liver (101) 101
familial hypercholesterolemia (100) 100
safety (98) 98
drug therapy, combination (97) 97
health aspects (97) 97
nutrition & dietetics (93) 93
rhabdomyolysis - chemically induced (93) 93
triglycerides (89) 89
low-density-lipoprotein (88) 88
rats, sprague-dawley (87) 87
adolescent (85) 85
care and treatment (85) 85
drug therapy (85) 85
coronary-heart-disease (84) 84
hypercholesterolemia - prevention & control (83) 83
hypertriglyceridemia - chemically induced (83) 83
inflammation (82) 82
pravastatin (82) 82
hiv infections - drug therapy (81) 81
hypercholesterolemia - physiopathology (81) 81
mice, inbred c57bl (81) 81
hypercholesterolemia - pathology (80) 80
atorvastatin (78) 78
mice, knockout (78) 78
prevention (78) 78
hypertension (77) 77
lipid metabolism (77) 77
lipoproteins - blood (77) 77
drug interactions (76) 76
lovastatin - adverse effects (76) 76
anticholesteremic agents - pharmacology (75) 75
arteriosclerosis - chemically induced (75) 75
cardiovascular disease (74) 74
cardiovascular diseases - prevention & control (74) 74
diet, atherogenic (74) 74
follow-up studies (74) 74
hypercholesterolemia - epidemiology (74) 74
simvastatin - adverse effects (74) 74
hypercholesterolemia - etiology (73) 73
efficacy (72) 72
lovastatin (71) 71
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1954) 1954
Russian (46) 46
German (45) 45
French (44) 44
Japanese (32) 32
Spanish (32) 32
Italian (9) 9
Polish (9) 9
Chinese (6) 6
Dutch (3) 3
Portuguese (2) 2
Romanian (2) 2
Bulgarian (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 2011, Volume 103, Issue 17, pp. 1299 - 1309
Journal Article
JAMA, ISSN 0098-7484, 12/2012, Volume 308, Issue 23, pp. 2497 - 2506
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 203 - 212
Adults with vascular disease were treated with a statin to lower LDL cholesterol and were assigned to receive either extended-release niacin plus laropiprant... 
NICOTINIC-ACID | LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | METABOLIC SYNDROME | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | PLACEBO-CONTROLLED TRIAL | NIACIN/LAROPIPRANT | DYSLIPIDEMIA | Follow-Up Studies | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Indoles - administration & dosage | Infection - chemically induced | Niacin - administration & dosage | Treatment Failure | Musculoskeletal Diseases - chemically induced | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Double-Blind Method | Risk Factors | Indoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus - chemically induced | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Drug Combinations | Dose-response relationship (Biochemistry) | Laropiprant | Blood circulation disorders | Care and treatment | Dosage and administration | Niacin | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Heart attacks | Risk groups | Diabetes mellitus | Cardiovascular disease | Low density lipoprotein | Cholesterol | Musculoskeletal system | Vascular diseases | Arteriosclerosis | Vitamin B | Skin | Lipoproteins (high density) | Drug dosages | Statins
Journal Article
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1580 - 1590
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 12/2016, Volume 118, Issue 12, pp. 1805 - 1811
Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall... 
CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | METAANALYSIS | EFFICACY | REDUCING LIPIDS | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | CARDIOVASCULAR-RISK PATIENTS | OUTCOMES | 9 SERINE-PROTEASE | EZETIMIBE | ATORVASTATIN | Back Pain - chemically induced | Myocardial Infarction - epidemiology | Humans | Middle Aged | Nasopharyngitis - chemically induced | Antibodies, Monoclonal - adverse effects | Coronary Disease - epidemiology | Hypercholesterolemia - drug therapy | Diabetes Mellitus, Type 2 - epidemiology | Clinical Trials, Phase III as Topic | Urinary Tract Infections - chemically induced | Respiratory Tract Infections - chemically induced | Stroke - epidemiology | Pruritus - chemically induced | Hypercholesterolemia - epidemiology | Acute Coronary Syndrome - epidemiology | Comorbidity | Ezetimibe - adverse effects | Angina, Unstable - epidemiology | Influenza, Human - chemically induced | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Clinical Trials, Phase II as Topic | Stroke (Disease) | Medical colleges | Analysis | Low density lipoproteins | Atherosclerosis | Monoclonal antibodies | Health aspects | Coronary heart disease | Antilipemic agents | Studies | Confidence intervals | FDA approval | Diabetes | Pruritus | Drug dosages | Patients
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 12/2016, Volume 68, Issue 12, pp. 2857 - 2866
Journal Article
Journal Article
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 12/2007, Volume 282, Issue 50, pp. 36275 - 36282
Compelling evidence indicates that excess consumption of sugar-sweetened beverages plays an important role in the epidemic of obesity, a major risk factor for... 
DIABETES-MELLITUS | HIGH-FAT | OBESITY | PRESENILINS | PROTEIN | DIET | LEARNING-DEFICITS | BIOCHEMISTRY & MOLECULAR BIOLOGY | IN-VIVO | MICE | US CHILDREN | Beverages - adverse effects | Glucose Intolerance - metabolism | Amyloid Precursor Protein Secretases - genetics | Diabetes Mellitus, Type 2 - genetics | Humans | Sweetening Agents - toxicity | Glucose Intolerance - pathology | Diabetes Mellitus, Type 2 - metabolism | Apolipoproteins E - metabolism | Obesity - genetics | Amyloidosis - chemically induced | Alzheimer Disease - pathology | Brain - metabolism | Hypercholesterolemia - pathology | Sucrose - toxicity | Amyloid beta-Peptides - genetics | Amyloidosis - genetics | Amyloid beta-Peptides - metabolism | Water - administration & dosage | Glucose Intolerance - chemically induced | Alzheimer Disease - chemically induced | Disease Models, Animal | Glucose Intolerance - genetics | Amyloidosis - pathology | Risk Factors | Insulin Resistance | Mice, Transgenic | Obesity - metabolism | Obesity - pathology | Amyloid Precursor Protein Secretases - metabolism | Animals | Apolipoproteins E - genetics | Obesity - epidemiology | Alzheimer Disease - metabolism | Brain - pathology | Mice | Diabetes Mellitus, Type 2 - chemically induced | Diabetes Mellitus, Type 2 - pathology | Hypercholesterolemia - chemically induced | Hypercholesterolemia - genetics | Alzheimer Disease - genetics | Hypercholesterolemia - metabolism | Amyloidosis - metabolism
Journal Article